1. Home
  2. BSVN vs NGNE Comparison

BSVN vs NGNE Comparison

Compare BSVN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank7 Corp.

BSVN

Bank7 Corp.

HOLD

Current Price

$49.53

Market Cap

416.1M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$34.41

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSVN
NGNE
Founded
2004
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.1M
744.9M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
BSVN
NGNE
Price
$49.53
$34.41
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$53.67
$63.57
AVG Volume (30 Days)
30.0K
310.4K
Earning Date
04-14-2026
05-08-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
0.93
EPS
1.25
N/A
Revenue
N/A
N/A
Revenue This Year
$5.05
N/A
Revenue Next Year
$4.05
N/A
P/E Ratio
$40.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.50
$15.93
52 Week High
$53.00
$43.66

Technical Indicators

Market Signals
Indicator
BSVN
NGNE
Relative Strength Index (RSI) 52.30 47.61
Support Level $40.17 $18.24
Resistance Level $53.00 $37.27
Average True Range (ATR) 1.56 3.04
MACD -0.34 -0.65
Stochastic Oscillator 36.94 17.67

Price Performance

Historical Comparison
BSVN
NGNE

About BSVN Bank7 Corp.

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: